The report on the Global Therapeutic Plasma Exchange Market gives an estimation of the development of the market based on historical studies and also provides forecasts on the basis of comprehensive research. The report gives a complete market analysis for the forecasted period from 2020 to 2026. The market is portioned into various segments with an in-depth outlook of the competitive outlook and a listing of the profiled key players. The market size in terms of revenue (USD MN) is calculated and provided for the study period along with the dynamics of the market such as the drivers and the restraints.
Major Drivers |
Major Restraints |
- Growing prevalence of neurological diseases
- Growing adoption of TPE procedures in rare disorders
- Rising awareness about increasing the clinical response rate of TPE procedures
|
- High cost of therapeutic plasma exchange procedures
- Lack of awareness about the TPE process
- Lack of skilled professionals
- Risks associated with therapeutic plasma exchange procedures
|
The comprehensive value chain analysis of the market will assist in attaining better product differentiation, along with detailed understanding of the core competency of each activity involved. The market attractiveness analysis provided in the report aptly measures the potential value of the market providing business strategists with the latest growth opportunities.
Leading Segment
- By Indication – Neurological Disorders
The report also covers the complete competitive landscape of the global Therapeutic Plasma Exchange market with company profiles of key players such as:
- Fresenius Se & Co. KGAA
- B. Braun Melsungen AG
- Baxter International Inc.
- Asahi Kasei Medical Co., Ltd.
- Terumo BCT, Inc.
- Haemonetics Corporation
- Kawasumi Laboratories, Inc.
- Hemacare Corporation
A detailed description of each has been included, with information in terms of H.Q, future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other latest industrial developments.
SEGMENTATIONS IN THE REPORT:
By Indication:
- Neurological Disorders
- Guillain–Barré Syndrome (GBS)
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Myasthenia Gravis
- Multiple Sclerosis
- Neuromylitis Optica
- Hematology Disorders
- Thrombotic Thrombocytopenic Purpura
- Cryoglobulinaemia
- Multiple Myeloma
- Waldenstrom Microglobulinaemia
- Hemolytic Uraemic Syndrome
- Renal Disorders
- Anti-GBM Disease (Goodpasture Syndrome)
- Wegner’s Granulomatosis (ANCA-associated Rapidly Progressive Glomerulonephritis)
- Post Renal Transplant Rejection
- Metabolic Disorders
- Familial Hypercholesterolemia (Homozygous)
- Autoimmune Disorders
- ANCA-associated Vasculitis
By Geography:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East And Africa
The Global Therapeutic Plasma Exchange Market has been exhibited in detail in the following chapters -
Chapter 1 Therapeutic Plasma Exchange Market Preface
Chapter 2 Executive Summary
Chapter 3 Therapeutic Plasma Exchange Industry Analysis
Chapter 4 Therapeutic Plasma Exchange Market Value Chain Analysis
Chapter 5 Therapeutic Plasma Exchange Market Analysis By Indication
Chapter 6 Therapeutic Plasma Exchange Market Analysis By Geography
Chapter 7 Competitive Landscape Of Therapeutic Plasma Exchange Companies
Chapter 8 Company Profiles Of Therapeutic Plasma Exchange Industry
METHODOLOGY:
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.